Dr. Mohit Kapoor

Director of the Arthritis Research Program at the Krembil Research Institute, University Health Network

Dr. Mohit Kapoor is the Director of the Arthritis Research Program (the largest multidisciplinary Arthritis Research Program in Canada) at the University Health Network (Toronto), where he is directing basic, clinical, and translational research in orthopedics, rheumatology, hand and osteoporosis programs. He is the Tier 1 Canada Research Chair in the Mechanisms of Joint Degeneration. Dr. Kapoor’s translational research program is directed towards: (1) Understanding the complex cellular and molecular mechanisms associated with joint destruction during osteoarthritis; (2) Identifying reliable biomarkers for early identification of patients with osteoarthritis to enable early intervention; (3) Identifying novel therapeutic targets to stop/delay osteoarthritis and restore joint function. His research is funded by various research organizations including the Canadian Institute of Health Research (CIHR), Canadian Foundation for Innovation (CFI), Natural Sciences and Engineering Research Council of Canada (NSERC), Krembil Foundation, The Arthritis Society, Stem Cell Network, etc. He also sits on review panels and boards of various research/funding organizations around the world. His work has been published in respected journals including Nature Medicine, Science Translational Medicine, Annals of The Rheumatic Diseases, Nature Reviews Rheumatology, etc.

Novel Therapeutic Strategies to Counteract Cartilage Destruction during Osteoarthritis

Monday, September 9, 3:30 PM – 4:00 PM


Osteoarthritis (OA) is among the most prevalent chronic human health disorders and the most common form of arthritis. It is among the leading causes of disability in Canada and worldwide; and with increasing life expectancy, OA is a major socioeconomic and clinical concern. In OA, cartilage is destroyed and synovium gets inflamed, causing joint stiffness, pain and disability. The disease progresses relatively unnoticed; by the time it is diagnosed, the damage is often so severe that treatments are no longer effective. Specific mechanisms associated with the joint destruction during OA are largely unknown. Due to the lack of biomarkers, it is impossible to identify patients exhibiting early stages of OA, leading to severe joint destruction. Furthermore, due to poor understanding of the underlying disease mechanisms, no disease-modifying therapies to treat OA exist. Therefore, early detection and early intervention are critical to restore joint functions. This lecture will provide an overview of the recent advancements in the field of osteoarthritis and potential therapeutic targets for the treatment of osteoarthritis.